GEORGE BAKRIS

Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CHICAGO, IL NPI 1821021619

General Payments — all program years on this page

$511,445.82

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 477
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $7,710.43 across 13 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $7,470.0010
Food and Beverage $240.433

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $3,150.004
Novo Nordisk AS $1,665.594
Acerta Pharma LLC $1,250.002
UCB SA $795.001
Merck Sharp & Dohme Corporation $700.001
Bayer HealthCare Pharmaceuticals Inc. $149.841

By program year

Program yearAmountRecords
2018 $108,632.18118
2019 $154,527.65119
2020 $65,328.7046
2021 $59,534.7457
2022 $80,268.5766
2023 $35,443.5558
2024 $7,710.4313

Records — PY2024 (13)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086173982 Bayer Healthcare Pharmaceuticals Inc. $149.84 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096551997 Novo Nordisk AS $450.00 03/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1096552137 Novo Nordisk AS $1,125.00 01/29/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1096552933 Novo Nordisk AS $225.00 01/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1096553433 Novo Nordisk AS $1,350.00 03/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1096941027 Novo Nordisk Inc $48.26 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097189348 Novo Nordisk Inc $1,125.00 06/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1097343794 Novo Nordisk Inc $42.33 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097735909 Novo Nordisk Inc $450.00 01/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1113951165 UCB SA $795.00 06/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1126677758 AstraZeneca Pharmaceuticals LP $750.00 05/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1126678536 AstraZeneca Pharmaceuticals LP $500.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141564297 Merck Sharp & Dohme LLC $700.00 04/24/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.